Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NurOwn (MSC-NTF) Phase 1/2 in ALS
NCT01051882Phase 2Completed
- Sponsor
- BrainStorm Cell Therapeutics Inc.
- Start
- Jun 2011
- Primary completion
- Dec 2012
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of MSC-NTF in amyotrophic lateral sclerosis (ALS), sponsored by BrainStorm Cell Therapeutics Inc.. Started Jun 2011; status: completed.
02
Drugs
MSC-NTF
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01051882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01051882.